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ABSTRACT
Introduction: A year into the pandemic, the knowledge of SARS-CoV-2 infection risks among healthcare workers remains
limited. In this cross-sectional study, we examined whether healthcare workers with high exposure to Covid-19 patients
had a higher risk of SARS-CoV-2 infection than other healthcare workers in a Norwegian University Hospital. We also inves-
tigated the prevalence of asymptomatic healthcare workers in a ward with a SARS-CoV-2 outbreak.
Methods: Healthcare workers from five wards at Akershus University Hospital were included between May 11 and June 11,
2020. Blood samples were analyzed for SARS-CoV-2 antibodies and seroprevalences compared between participants with
high and low exposure to Covid-19 patients. Demographic data and SARS-CoV-2 infection risk factors were recorded in a
questionnaire. Naso-/oropharyngeal swabs from participants from the outbreak ward were analyzed by reverse transcript-
ase-polymerase chain reaction.
Results: 360/436 (82.6%) healthcare workers participated. 9/262 (3.4%) participants from wards with high exposure to
Covid-19 patients were SARS-CoV-2 seropositive versus 3/98 (3.1%) from wards with low exposure (OR 1.13; 95%CI
0.3–4.26, p¼ .861). SARS-CoV-2 antibodies were found in 11/263 (4.2%) participants who had worked one or more shifts
caring for Covid-19 patients versus in 1/85 (1.2%) without any known occupational Covid-19 exposure (OR 3.67; 95%CI
0.46–29.06, p¼ .187). SARS-CoV-2 was detected in naso-/oropharyngeal swabs from 2/78 (2.6%) participants.
Conclusion: We found no significantly increased risk of SARS-CoV-2 infection in healthcare workers with high exposure to
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Introduction
Reports of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infections among healthcare
workers (HCWs) vary substantially between countries
affected by the pandemic [1–7]. Assessing the true
work-related risk of infection is difficult as HCWs are
exposed to SARS-CoV-2 infection both in the community
and at work. Therefore, the risk of infection will depend
on many factors, including the SARS-CoV-2 prevalence
in the community, national and local strategies to com-
bat the virus, organization of healthcare and infection
prevention and control (IPC) routines, including access
to, and proper use of, personal protective equip-
ment (PPE).
In this cross-sectional study, performed in a
Norwegian University Hospital, we examined the risk of
SARS-CoV-2 infection among HCWs in a setting with low
community prevalence and high standard of IPC rou-
tines. The aim was to determine whether HCWs in
Covid-19 wards had a higher risk of SARS-CoV-2 infec-
tion than other HCWs by comparing seroprevalences in
the two groups. In addition, the prevalence of asymp-
tomatic HCWs in a ward with an ongoing SARS-CoV-2
outbreak was investigated by analyzing naso-/oropha-




Akershus University Hospital is the largest acute care
hospital in Norway with 1000 beds and 10,000 employ-
ees, serving 640,000 people (10% of the Norwegian
population). The SARS-CoV-2 seroprevalence in the two
counties within the hospital’s catchment area was esti-
mated at approximately 1.4% (0.1 4.9%)4.2%
(0.9 10.4%) in AprilMay 2020 [8]. The hospital
received the first Covid-19 patient on March 5, 2020.
One hundred forty-seven Covid-19 patients had received
treatment and 54 hospital employees had tested posi-
tive for SARS-CoV-2 (symptom-based testing) by the
time the study commenced.
Built in 2008, the hospital buildings are modern with
mainly single or double rooms with separate toilets,
both in the regular wards and in the intensive care unit
(ICU). Barrier precautions were applied around each
Covid-19 patient, and none of the wards included in the
study had any cohort areas with more than two
patients. Mandatory use of PPE and enhanced IPC
routines were implemented in March 2020 for staff,
patients and visitors. Still, in one Covid-19 ward an accu-
mulation of SARS-CoV-2 infections among HCWs over
the course of four weeks indicated a possible ongoing
outbreak at the start of the study. Transmission between
staff members mediated by pre- or asymptomatic per-
sons was considered a possibility.
Data collection
HCWs were invited from five wards: Covid ward A
(N¼ 92), Covid ward B (N¼ 75), ICU (N¼ 148), an ortho-
paedic ward (N¼ 70) and the Department of
Microbiology and Infection Control (N¼ 51). HCWs in
the first three wards had high exposure to Covid-19
patients whereas HCWs in the last two wards had little
or no known work-related exposure. Exposure at work
was defined primarily by a HCW’s affiliation with a ward.
However, since some Covid-19 patients admitted due to
orthopaedic disorders were treated in the orthopaedic
ward, and some orthopaedic HCWs were re-allocated to
high-exposure wards, the number of shifts HCWs spent
caring for Covid-19 patients was also recorded.
The HCWs were recruited from May 11 to June 11,
2020. Blood samples for analysis of SARS-CoV-2 antibod-
ies were collected on the day of study inclusion and a
paper questionnaire filled in, which recorded demo-
graphic data and SARS-CoV-2 infection risk factors,
including infection control training and routines
(Appendix A). In addition, naso-/oropharyngeal swabs
were collected from HCWs from the outbreak ward for
analysis by RT-PCR.
Serology
Blood samples were collected using VacuetteVR Tube
(Greiner Bio-One, Kremsm€unster, Austria). The samples
were centrifuged at 2000G within 2 h after sampling and
stored in 20 C. All serum samples were analyzed with
the ElecsysVR Anti-SARS-CoV-2 immunoassay (Roche
Diagnostics, Basel, Switzerland) on an automated platform
(CobasVR , Roche Diagnostics, Basel, Switzerland). The
immunoassay detects IgG/IgM to the SARS-CoV-2 nucleo-
capsid antigen [9]. Based on an in-house validation, the
hospital laboratory has introduced an equivocal zone and
uses the following cut-off index (COI): Non-reactive
(<0.5), equivocal zone (0.5–<1) and reactive (1). To
ensure high specificity, samples with equivocal or unex-
pected reactive test results (participants without prior
knowledge of SARS-CoV-2 infection) were retested with
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the Roche test, and with a second test, the LiaisonVR
SARS-CoV-2 S1/S2 IgG (DiaSorin, Saluggia, Italy), which
detects SARS-CoV-2 spike IgG [10]. For one study partici-
pant, two samples were in addition analyzed with two
more tests in external laboratories (Appendix B).
Reverse transcriptase-polymerase chain reaction
Naso-/oropharyngeal samples were collected in an
inhouse viral transport medium and analyzed with RT-
PCR for the detection of SARS-CoV-2 on the day of sam-
pling. RNA was isolated with easyMAGVR (BioMerieux,
Marcy-l’Etoile, France). The RT-PCR is a validated, in-
house, qualitative RT-PCR detecting the SARS-CoV-2 viral
envelope gene, based on a method published by
Corman et al. [11].
Statistics
Microsoft Excel (version 2010) and the statistical soft-
ware package STATA (version 16) were used for data
analysis. SARS-CoV-2 seroprevalences were compared
between HCWs with high and low exposure to Covid-19
patients, both grouped by wards and by self-reported
exposure. p-values were calculated using either logistic
regression for categorical variables with more than two
categories or a chi-squared test for 2 2 tables (with p-
values  .05 considered to indicate statistical
significance).
Ethics committee approval
Ethical approval was granted from the Norwegian
Regional Committee for Medical and Health Research
Ethics on May 4, 2020 (REK ref 138484) and from the
Akershus University Hospital’s local Data Protection
Official on May 8, 2020 (PVO ref 2020_67). Written
informed consent was obtained from all study
participants.
Results
Study participants and demographic data
Of the 436 HCWs invited, 360 (82.6%) participated in the
study. The questionnaire was filled in by 358 (99.4%)
participants. Demographic and clinical characteristics are
presented in Table 1.
SARS-CoV-2 serology
SARS-CoV-2 antibodies were detected in 12/360 (3.3%)
participants (Table 2), where nine had previous PCR-con-
firmed SARS-CoV-2 infection (eight before study inclu-
sion and one at study inclusion from the outbreak
ward). Three HCWs (one each from Covid ward B, the
ICU and the orthopaedic ward) had positive SARS-CoV-2
serology without a previous diagnosis of Covid-19. In
four HCWs, additional blood sampling after 5–6weeks
was necessary to reach a conclusion about serological
status due to equivocal or unexpected positive results
(Appendix B).
Association between SARS-CoV-2 seropositivity and
exposure at work
The results are summarized in Table 2. SARS-CoV-2 anti-
bodies were detected in nine (3.4%) HCWs in the high
exposure wards versus in three (3.1%) in the low/no
exposure ward, with an OR of 1.13 (95%CI 0.3 4.26,
p¼ .861). SARS-CoV-2 antibodies were found in 11
(4.2%) HCWs who had worked at least one or more
shifts with Covid-19 patients versus in one (1.2%) who
had no occupational exposure to Covid-19 patients. The
OR was 3.67 (95%CI 0.46 29.06, p¼ .187).
Two of the SARS-CoV-2 infected HCWs in the ward
with an outbreak did not participate in the study.
However, calculations show that their participation
would not have changed the interpretation of the asso-
ciation between SARS-CoV-2 seropositivity and exposure
at work.
Risk factors related to work
Possible risk factors for SARS-CoV-2 infection related to
work are summarized in Table 3. The participants had
two opportunities for free text comments: one regarding
any additional breaches of IPC routines except those
listed in the questionnaire, and one regarding any fur-
ther comments on working during the Covid-19 epi-
demic. As the free text comments mainly addressed the
same issues, results are presented in Figure 1. Concerns
regarding poorly fitting PPE and lack or reuse of PPE
were the most frequent issues.
SARS-CoV-2 RT-PCR
SARS-CoV-2 was detected by RT-PCR in two (2.6%) of
the 78 HCWs tested from the outbreak ward. The first
HCW had mild upper respiratory symptoms assumed to
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be allergy. Another sample was taken the next day to
exclude a false-positive test or laboratory mistake, but
the second sample was also positive. The second HCW
was asymptomatic at the time of testing, but symptoms
appeared around 12 h later, and the HCW was reclassi-
fied as a presymptomatic case.










Department 360 262 98
Covid A 80 (22.2%) 80 (30.5%) –
Covid B 61 (16.9%) 61 (23.3%) –
Intensive care unit 121 (33.6%) 121 (46.2%) –
Orthopaedic ward 49 (13.6%) – 49 (50%)
Dep. Microbiology/Infection Control 49 (13.6%) – 49 (50%)
Occupation 360 262 98
Doctors 106 (29.4%) 79 (30.2%) 27 (27.6%)
Nurses 199 (55.3%) 169 (64.5%) 30 (30.6%)
Healthcare assistants 18 (5%) 14 (5.3%) 4 (4.1%)
Biomedical laboratory scientists 32 (8.9%) 0 32 (32.7%)
Researchers/consultants 5 (1.4%) 0 5 (5.1%)
Gender 360 262 98
Female 275 (76.4%) 197 (75.2%) 78 (79.6%)
Male 85 (23.6%) 65 (24.8%) 20 (20.4%)
Age 360 262 98
40 years 187 (51.9%) 134 (51.1%) 53 (54.1%)
41–60 years 156 (43.3%) 118 (45%) 38 (38.8%)
61 years 17 (4.7%) 10 (3.8%) 7 (7.1%)
Comorbiditiesb 339 245 94
Asthma or COPD 27 (8.0%) 21 (8.6%) 6 (6.4%)
High blood pressure (medicated) 18 (5.3%) 11 (4.5%) 7 (7.4%)
Heart failure or myocardial infarction 2 (0.6%) 0 2 (2.1%)
Diabetes mellitus (types I or II) 6 (1.8%) 4 (1.6%) 2 (2.1%)
Immunological diseasec 3 (0.9%) 1 (0.4%) 2 (2.1%)
Cancer (currently treated) 1 (0.3%) 1 (0.4%) 0
None of these 289 (85.3%) 211 (86.1%) 78 (83%)
Missing data 19 15 4
Immunosuppressive medicine 355 257 98
Yes 8 (2.3%) 5 (1.9%) 3 (3.1%)
No 347 (97.8%) 252 (98.1%) 95 (96.9%)
Missing data 3 3 0
Pregnant 260 187 73
Yes 12 (4.4%) 7 (3.7%) 5 (6.8%)
No 248 (90.5%) 180 (96.3%) 68 (93.2%)
Missing data 15 10 5
Symptoms after February 1, 2020b 354 256 98
Cough 125 (35.3%) 100 (39.1%) 25 (25.5%)
Fever 36 (10.2%) 30 (11.7%) 6 (6.1%)
Breathlessness 43 (12.2%) 32 (12.5%) 11 (11.2%)
Loss of taste or sense of smell 12 (3.4%) 10 (3.9%) 2 (2%)
Headache 165 (46.6%) 117 (45.7%) 48 (49%)
Muscle ache 56 (15.8%) 44 (17.2%) 12 (12.2%)
Stuffy/runny nose 162 (45.8%) 118 (46.1%) 44 (44.9%)
Sore throat 152 (42.9%) 114 (44.5%) 38 (38.8%)
General malaise 86 (24.3%) 62 (24.2%) 24 (24.5%)
Abdominal pain 42 (11.9%) 31 (12.1%) 11 (11.2%)
Nausea 34 (9.6%) 25 (9.8%) 9 (9.2%)
Unusual loose stools 24 (6.8%) 17 (6.6%) 7 (7.1%)
No symptoms 73 (20.6%) 50 (19.5%) 23 (23.5%)
Missing data 4 4 0
SARS-CoV-2 PCR test before study 358 260 98
Yes 119 (33.2%) 95 (36.5%) 24 (24.5%)
No 239 (66.8%) 165 (63.5%) 74 (75.5%)
SARS-CoV-2 PCR result before study 118 94 24
Positive 8 (6.8%) 6 (6.4%) 2 (8.3%)
Negative 110 (93.2%) 88 (93.6%) 22 (91.7%)
Missing data 1 1 0
aThe percentage is calculated using the total number of answers as the numerator (i.e. excluding missing data).
bMultiple choices possible.
cRheumatoid arthritis or systemic lupus erythematosus.
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Discussion
We compared the SARS-CoV-2 seroprevalence in HCWs
with high and low occupational exposure to Covid-19
patients. There was no evidence of a significantly
increased risk of SARS-CoV-2 infection in HCWs with
high exposure, grouped by either wards or number of
shifts treating Covid-19 patients. These findings are in
accordance with other studies which found no increased
infection risk among HCWs caring for Covid-19 patients
[12–14]. However, intra-hospital transmission cannot be
ruled out in any of the HCWs in our study. Further, the
results must be interpreted with caution due to the low
number of seropositive HCWs in both groups, which
makes the study vulnerable to type II error. Other stud-
ies have reported a significantly higher prevalence in
HCWs than in the community [4,15–19], suggesting an
occupational hazard and emphasizing the importance of
robust IPC measures to protect HCWs. While proper use
of PPE has proven protective in several studies [20,21],
long working hours, high work intensity, work in either
Table 2. Association between SARS-CoV-2 seropositivity and exposure at work.
Total
SARS-CoV-2 seropositive
N1 (%)a N2 (%)b Crude OR (95% CI) p Value
Department 360
Covid A 80 (22.2%) 6 (7.5%) 1.24 (0.30 5.22) .766
Covid B 61 (16.9%) 2 (3.3%) 0.52 (0.08 3.24) .483
Intensive care unit 121 (33.6%) 1 (0.8%) 0.13 (0.01 1.26) .078
Orthopaedic ward 49 (13.6%) 3 (6.1%) 1.00 (reference)
Dep. Microbiology/Infection Control 49 (13.6%) 0 –
Department, grouped by exposure 360
High exposure (Covid A, Covid B, ICU) 262 (72.8%) 9 (3.4%) 1.13 (0.30 4.26) .861
Low exposure (orthopaedic and MIC) 98 (27.2%) 3 (3.1%) 1.00 (reference)
Work exposure Covid-19 348
>30 shifts on ward w/ Covid-19 patients 132 (37.9%) 3 (2.3%) 1.65 (0.17 16.17) .667
11–30 shifts on ward w/ Covid-19 patients 75 (21.6%) 5 (6.7%) 5.07 (0.58 44.52) .143
<10 shifts on ward w/ Covid-19 patients 56 (16.1%) 3 (5.4%) 4.02 (0.41 39.72) .234
Handled Covid-19 samples at the lab 13 (3.7%) 0 –
No known exposure 72 (20.7%) 1 (1.4%) 1.00 (reference)
Missing data 10
Work exposure Covid-19, grouped 348
Any shifts on ward with Covid-19 patients 263 (75.6%) 11 (4.2%) 3.67 (0.46 29.06) .187
Samples at lab/no known ward exposure 85 (24.4%) 1 (1.2%) 1.00 (reference)
aThe percentage is calculated using the total number of answers as the numerator (i.e. excluding missing data).
bN2¼ number of seropositives out of the total number in each row.
Table 3. Possible risk factors for SARS-CoV-2 infection related to work.
Total N (%)a
Wards with high exposure to Covid-19
patients N (%)a
Wards with low exposure to Covid-19
patients N (%)a
PPE training after 1st March 2020 351 253 98
Received training 247 (70.4%) 212 (83.8%) 35 (35.7%)b
Received no training 63 (17.9%) 33 (13%) 30 (30.6%)
Not applicable to the HCW 41 (11.7%) 8 (3.2%) 33 (33.7%)
Missing data 7 7 0
Experience with PPE/IPC routinec 294 214 80
Damaged/nonfunctional PPE 76 (25.9%) 71 (33.2%) 5 (6.3%)
Lack of PPE 86 (29.3%) 75 (35%) 11 (13.8%)
Other breaches of IPC routines 57 (19.4%) 52 (24.3%) 5 (6.3%)
Not applicable to the HCW 126 (42.9%) 64 (29.9%) 62 (77.5%)
Missing data 64 46 18
Experienced any IPC routine breaches 294 214 80
Yes 171 (58.2%) 151 (70.6%) 20 (25%)
No or Not applicable to the HCW 123 (41.8%) 63 (29.4%) 60 (75%)
Missing data 64 46 18
Worked in other wards of the hospital 356 259 97
Yes 97 (27.2%) 80 (30.9%) 17 (17.5%)
No 259 (72.8%) 179 (69.1%) 80 (82.5%)
Missing data 2 1 1
Worked in other healthcare services
outside the hospital
355 258 97
Yes 19 (5.4%) 15 (5.8%) 4 (4.1%)
No 336 (94.6%) 243 (94.2%) 93 (95.9%)
Missing data 3 2 1
aThe percentage is calculated using the total number of answers as the numerator (i.e. excluding missing data).
b32/49 (65.3%) HCWs from the orthopaedic ward had received PPE training.
cMultiple choices possible.
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high or low exposure wards, inadequate PPE, insufficient
IPC training, lack of monitoring of IPC routines and poor
hand hygiene have been identified as risk factors for
contracting SARS-CoV-2 in healthcare settings [1,22–24].
In our study, it was reassuring that the majority of HCWs
in patient care had received training in the use of PPE
during the pandemic, but worrying that more than half
of the responding participants had experienced one or
more breaches in IPC routines. Most of those breaches
pertained to poorly fitting PPE and reuse of PPE, which
resulted from the sudden rise in global demand for, and
subsequent lack, of PPE.
A secondary objective in our study was to examine
whether asymptomatic carriage of SARS-CoV-2 in HCWs
was prevalent in a ward with a possible outbreak. Two
HCWs tested SARS-CoV-2 positive in naso-/oropharyn-
geal swabs. None was truly asymptomatic, as one had
very mild upper respiratory symptoms and the other
was a presymptomatic case. In addition, three HCWs
from other wards had positive SARS-CoV-2 serology
without any previous diagnosis of Covid-19, probably
due to the absence of notable symptoms. This shows
that HCWs may unknowingly be at work during an
infectious stage of SARS-CoV-2 infection, being either
asymptomatic, presymptomatic or with mild symptoms
as mistakenly attributed to other causes. Almost 80% of
the study participants had experienced at least one or
more respiratory, gastrointestinal or other symptoms in
the past three months, but only 12 (3.3%) participants
had positive SARS-CoV-2 serology. The upcoming cold
season might thus pose challenges in balancing work
restrictions for HCWs with symptoms that cannot empir-
ically be excluded as related to SARS-CoV-2 infection
while securing enough staff at work. Planning of hos-
pital activities should take this into account.
Despite several reports of outbreaks in healthcare set-
tings [25–27], the extent to which asymptomatic or pre-
symptomatic SARS-CoV-2 infection contributes to
transmission among colleagues and patients in health-
care settings is still poorly understood [28]. The most
infectious period of SARS-CoV-2 infected individuals is
right before and at the time of onset of symptoms,
when the viral load in the upper airways is highest
[29,30]. Several studies have found no difference in the
viral load of nasal swabs between asymptomatic and
symptomatic cases [31,32]. This indicates a high poten-
tial for asymptomatic and presymptomatic transmission.
However, even if the viral load in the airways is compar-
able in asymptomatic and symptomatic patients, the
presence of cough, sneezing or nasal secretion is likely
to enhance viral transfer, and several studies have con-
cluded that asymptomatic cases transmit less virus than
symptomatic cases [33–36]. This conclusion is supported
by our study, as no outbreaks were recorded among
employees or patients in the wards of the three HCWs
with an unexpected positive serology. Transmission
between the two RT-PCR positive HCWs from the out-
break ward was deemed likely based upon epidemio-
logical data and whole-genome sequencing (data to be
published), but these HCWs were not asymptomatic.
Limitations
As the seropositivity rate was low in both groups, a type II
error cannot be ruled out. Power calculations showed that
we could not detect any true difference less than 8.9%
between the two groups. Further, it is not clear whether
everyone infected develops antibodies, especially those
with only mild symptoms [37]. Although all HCWs with a
PCR-confirmed SARS-CoV-2 infection had detectable SARS-
CoV-2 antibodies, false-negative tests cannot be excluded.
Conclusion
In conclusion, we found no significantly increased risk of





9 (9%)Poor quality of PPE
Concerns regarding reuse or lack of PPE
Dissatisfaction regarding IPC routines
IPC breaches due to communication or training issues
Comments regarding physical or psychological welfare
Other comments
Figure 1. Free text comments regarding PPE and IPC routines during work with Covid-19 patients (N¼ 104 comments).
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Covid-19 patients in our hospital. Five HCWs had either
serologic or molecular evidence of past or present SARS-
CoV-2 infection without being aware of having been
infected. More studies are needed to assess the infection
risks to HCWs caring for Covid-19 patients as well as the
role HCWs play in-hospital transmission, including
asymptomatic or presymptomatic HCWs. Meanwhile,
health authorities should monitor SARS-CoV-2 infection
in HCWs to ensure safe working conditions by adjusting
and facilitating the adherence to appropriate
IPC measures.
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Study ID:________________________________________________________________
Year of birth: ____________________________________________________________
Date the form is filled in: __________________________________________________
1) Gender:
☐ Man ☐ Woman ☐ Other
2) Position:
☐ Senior consultant ☐ Jr consult. ☐ Nurse ☐ Assistant nurse
☐ Bioengineer ☐ Health Secretary/consultant ☐ Other:______________
3) Are you pregnant?
☐ Yes ☐ No ☐ Not relevant
4) Do you have any of the following diseases? Multiple choices possible
☐ Asthma or COPD
☐ High blood pressure treated with medications
☐ Rheumatoid arthritis or Systemic lupus erythematosus
☐ Heart failure or myocardial infarction
☐ Cancer currently treated
☐ Diabetes mellitus (type I or II)
☐ None of these
5) Do you/have you since 1st March 2020 use/used immunosuppressive medicine such as: Prednisolone> 20mg/day, CellCept, cytostatic drugs, TNF-a
inhibitor or other?
☐ Yes ☐ No
6) a) Number of adults, 18 years or older, in the household except yourself: _____
b) Number of children under the age of 18 years in the household: __________





☐ Fever (>38 C)
☐ Headache
☐ Loss of taste or sense
of smell
☐ Breathlessness




☐ Unusual loose stool
☐ No symptoms
8) Have you previously been tested for Covid-19? (prior to inclusion in this study)
a) ☐ Yes ☐ No
b) If yes – date: __________________
c) Test result:
☐ Detected ☐ Not detected
9) Have you travelled abroad after 1st of February 2020?
☐ Yes ☐ No
10) a) Have you been in close contact with someone with confirmed Covid-19 except at work?
Close contact is defined as: a) Had physical contact or b) been with someone with Covid-19 at less than 2 metres distance for more than 15min.
☐ Yes ☐ No
b) If yes, who? Multiple choices possible
☐ Spouse/sexual partner
☐ Other household member
☐ Friend
☐ Own children in the household
☐ Family member outside the household
☐ Other contact
11) Has your partner or one or more of your household members had possible Covid-19 symptoms without being tested?
☐ Yes ☐ No
12) If you have had symptoms/Covid-19 and have been in close contact with someone with proven Covid-19: When did your symptoms occur?
Close contact is defined as: a) Had physical contact or b) been with someone with Covid-19 at less than 2 metres distance for more than 15min.
☐ Before the close contact got symptoms
☐ After the close contact got symptoms
☐ Don’t know
☐ I didn’t have close contact with anyone with Covid-19
☐ I haven’t had symptoms
13) Check where you have worked in the period between 1st March 2020 to the present day:
Multiple choices possible
☐ Covid 1 (Infectious medicine ward)
☐ Covid 2 (Pulmonary ward)





☐ Department of Microbiology and Infection Control
☐ None of these. Which: _______________
14) Have you worked in other units at Ahus in the period between 1st March 2020 and now?
a) ☐ Yes ☐ No
b) If yes, what other wards have you worked in? ____________________________
15) Have you worked in other healthcare services except Ahus in the period between 1st March 2020 and now? (e.g. nursing homes, community
emergency care, home nursing, etc.)
☐ Yes ☐ No
16) To what extent have you worked with patients with confirmed Covid-19 at Ahus:
☐ In total> 30 shifts on a ward with Covid-19 patients
☐ In total 11-30 shifts on a ward with Covid-19 patients
☐ In total< 10 shifts on a ward with Covid-19 patients
☐ Handled Covid-19 samples at the lab
☐ I have no known exposure to Covid-19 patients or sample material at work
(continued)
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Questionnaire CoVProtect Study (English translation)
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17) Use of personal protective equipment for employees who have treated patients with Covid-19 or sample material from Covid-19 patients:
Check if the statement matches any experience you have had at work during the Covid-19 epidemic. Multiple choices possible.
☐ I have experienced that protective equipment has broken and lost function during use
☐ I have experienced a lack of personal protective equipment which has led to a violation of the infection prevention and control routines
☐ I have experienced other breaches of infection prevention and control routines,
describe:____________________________________________________________
☐ Not applicable to me
18) Have you under the pandemic used personal protective equipment that you have been uncertain how best to use?
☐ Yes ☐ No ☐ Not applicable to me
19) Have you been trained in the use of personal protective equipment one or more times during the period between 1st January and 1st March 2020?
☐ Yes ☐ No ☐ Not applicable to me
20) Have you received training in the use of personal protective equipment after 1st March 2020?
☐ Yes ☐ No ☐ Not applicable to me





☐ Not applicable to me
22) Do you have any other comments related to your work with Covid-19 patients?
ElecsysV
R
Anti-SARS-CoV-2 LiaisonVR SARS-CoV-2 S1/S2 IgG Conclusion
HCW 1:
Sample 1 Equivocal (COI 0.557) – Non-reactive
Sample 2 Non-reactive (COI 0.239) Non-reactive (3.8 AU/ml)
HCW 2:
Sample 1 Equivocal (COI 0.505) Non-reactive (10 AU/ml) Reactive (IgM in first sample,
IgG in second sample)Sample 2 Reactive (COI 1.710) Reactive (37.5 AU/ml)
HCW 3:
Sample 1 Reactive (COI 58.7) Reactive (33.3 AU/ml) Reactive (excluded lab mistake)
Sample 2 Reactive (COI 90.1) Reactive (125 AU/ml)
HCW 4:
Sample 1 Reactive (COI 119) Non-reactive (9.74 AU/ml) Reactive (IgG only towards nuclecapsid,
not spike antigen)aSample 2 Reactive (COI 137) Non-reactive (8.49 AU/ml)
aThe samples were in addition tested with Abbott SARS-CoV-2 IgG assay (Abbott, IL) in an external laboratory, which was reactive. In a further analysis with an in-
house test in another external laboratory, the sample tested reactive towards SARS-CoV-2 nucleocapsid antigen and one of two receptor binding domains on the
spike protein, but negative towards spike IgG.
Appendix B
SARS-CoV-2 analysis of first and second samples in four participants
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